Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
COR · NYSE · Health Care Distributors
Cencora (COR) · oqro.io/stocks/COR · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$348.31−2.25 (−0.64%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
No open-market purchase by an insider of Cencora was filed in the last 90 days. The latest on record was on Jun 25, 2026.
Since 2006, Cencora insiders reported 22 open-market purchases and 529 sales on Forms 4 and 5, with purchases in 10 different years, most recently 2026.
In the last 90 days, 3 insiders of Cencora (COR) reported 5 open-market sales worth $5.02M in total on SEC Form 4. The largest seller by value was Elizabeth S Campbell, with $3.66M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 6 trades in Cencora (COR) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Sen. Alan Armstrong, Rep. Jared Moskowitz (FL23).
Cencora's next results are expected on Feb 2, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−3.7% (−$13.33) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $361.64 on Nov 18, 2025 to $348.31 on Nov 18, 2026 (−3.7%). Disclosed in this range: 13 insider trades, 3 pre-arranged insider sales, 6 Congress trades, and 82 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Distributors company based in Conshohocken, Pennsylvania.
Last 12 months
−3.7%
Market value
$66.5B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 3.16M shares sold short (1.7% of shares outstanding), −19.8% vs the previous count, 2.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$84.8B
+5.1% vs the same quarter a year earlier
Free cash flow, last 12 months
$4.06B
This quarter $2.43B, a year earlier −$74M
Net debt
$8.91B
Debt $11.7B, cash $2.82B, at Jun 30, 2026
Net income, last 12 months
$2.62B
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Revenue, fiscal 2025
$321B
+9.3% vs the year before
Net income, fiscal 2025
$1.55B
As reported in the annual filing
Shares outstanding
191M
As of Jul 31, 2026
In fiscal 2025 the company spent $435M buying back its own shares and $437M on dividends. Cash actually paid, from its cash-flow statement.
New federal contracts from the last 12 months add up to 0.02% of that revenue. Contract money is usually earned over several years, so this is a size comparison, not a share of sales.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Lazarus Krikorian (SVP & Chief Accounting Officer) sold ~$326K of Cencora
Insider selling
Traded Oct 1 · filed 4 days laterNot reported under a pre-arranged trading plan
Since the trade +12.4% · S&P 500 −4.4% · to Nov 18
Cencora's SVP & Chief Accounting Officer sold $299K of Cencora shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Sep 16 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade +9.4% · S&P 500 −3.2% · to Nov 18
A Cencora director sold $411K of Cencora shares. The filing does not indicate a pre-arranged trading plan.
Lon Greenberg (Director) plans to sell ~$411K of Cencora
Planned, from payPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Written by software from the filings listed below · Oct 16, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeTop officer leaving
“Cleary will retire as Executive Vice President and Chief Financial Officer of the Company effective June 30, 2026.”
1 insider sold ~$3.64M in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Insiders of Cencora reported 22 open-market purchases and 529 sales since 2006; purchases in 10 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $2.31M3×3 trades | $8.66M8×8 trades |
| 2025 | — | $378M37×37 trades |
| 2024 | $109K1×1 trade | $2.53B22×22 trades |
| 2023 | — | $665M38×38 trades |
| 2022 | — | $3.99B33×33 trades |
| 2021 | — | $70.5M38×38 trades |
| 2020 | $202K2×2 trades | $39.1M43×43 trades |
| 2019 | $157K4×4 trades | $38.4M31×31 trades |
| 2018 | $1.2K2×2 trades | $48.5M67×67 trades |
| 2017 | — | $33.6M39×39 trades |
| 2016 | $354K1×1 trade | $29.4M14×14 trades |
| 2015 | $593K5×5 trades | $92.1M41×41 trades |
| 2014 | — | $37.7M13×13 trades |
| 2013 | $3221×1 trade | $43.8M19×19 trades |
| 2012 | $3962×2 trades | $18.3M20×20 trades |
| 2011 | $1501×1 trade | $31.7M10×10 trades |
| 2010 | — | $55.3M18×18 trades |
| 2009 | — | $21.4M21×21 trades |
| 2008 | — | $4.76M3×3 trades |
| 2007 | — | $20.8M4×4 trades |
| 2006 | — | $16.7M10×10 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the public record for Cencora over the 12 months to Nov 18, 2026: 4 FDA records and 2 executive contributions.
Against the S&P 500 over the year
Since Nov 14, 2025, COR is down 3.1% and the index fund is up 9.0%: 12 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much COR moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
0 approvals or clearances and 4 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Last results
Nov 4, 2026
Within the 30 days after it, until Dec 4, 2026
Next results, expected
Feb 2, 2027
Purchases after results
20%
2 of 10 insider purchases since 2019 came within 30 days after a results announcement
From Cencora's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Cencora's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Short sale volume: 43.5% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 46.3%. FINRA daily files, to Nov 18, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.